van Nijnatten Thiemo J A, de Mooij Cornelis M, Mitea Cristina, Houwers Janneke, de Boer Maaike, Smidt Marjolein L, Mottaghy Felix M, Wildberger Joachim E
Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands.
GROW-Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands.
Insights Imaging. 2024 Oct 9;15(1):243. doi: 10.1186/s13244-024-01830-5.
To investigate in a feasibility study the combination of [F]FDG whole-body (WB) positron emission tomography-magnetic resonance (PET-MR), including an integrated breast MR within a single protocol for locoregional and distant staging in breast cancer patients.
Consecutive patients with breast cancer diagnoses according to conventional imaging modalities (full-field digital mammography (FFDM) and ultrasound (US)) were prospectively included. All patients underwent [F]FDG WB PET-MR, including an integrated dedicated breast MR (prone position) and WB PET-MR (supine position) protocol. Results of [F]FDG WB PET-MR, including integrated breast MR, versus conventional imaging modalities were compared.
From April 2021-April 2022, 28 patients were included. On conventional imaging, cT1-2 breast cancer was present in 22 (FFDM) and 23 (US) out of 28 patients. With regard to clinical nodal status, eight patients were considered cN0, eighteen cN1 (1-3 suspicious lymph nodes), and two patients were cN2 (four suspicious axillary lymph nodes/internal mammary lymph node metastasis). [F]FDG WB PET-MR, including an integrated breast MR protocol, upstaged clinical tumor status in two patients and clinical nodal status in nine patients according to both [F]FDG WB PET-MR and breast MR findings. In addition, distant metastases were detected in three patients (liver/bone), and another patient was diagnosed with a synchronous primary tumor (lung cancer).
[F]FDG WB PET-MR, including an integrated breast MR within a single protocol in breast cancer patients, is feasible and provides a promising new approach in breast cancer patients with regard to locoregional and distant staging. CRITICAL RELEVANCE STATEMENT: [F]FDG whole-body PET-MR, including an integrated breast MR protocol, is feasible and allows locoregional and distant staging within a single imaging exam in breast cancer patients.
[F]FDG PET-MR allows the combination of breast MR and whole-body staging. Therefore, a single protocol of whole-body [F]FDG PET-MR, including an integrated breast MRI, is investigated. [F]FDG PET-MR, including an integrated breast MR is feasible and can be considered in daily clinical practice.
在一项可行性研究中,探讨[F]氟代脱氧葡萄糖([F]FDG)全身正电子发射断层扫描-磁共振成像(PET-MR)的联合应用,包括在单一方案中进行乳腺磁共振成像(MR)整合,用于乳腺癌患者的局部区域和远处分期。
前瞻性纳入根据传统成像方式(全视野数字化乳腺摄影(FFDM)和超声(US))诊断为乳腺癌的连续患者。所有患者均接受[F]FDG全身PET-MR检查,包括整合的专用乳腺MR(俯卧位)和全身PET-MR(仰卧位)方案。比较[F]FDG全身PET-MR(包括整合的乳腺MR)与传统成像方式的结果。
2021年4月至2022年4月,共纳入28例患者。在传统成像中,28例患者中有22例(FFDM)和23例(US)为cT1-2期乳腺癌。关于临床淋巴结状态,8例患者被认为是cN0,18例为cN1(1-3个可疑淋巴结),2例为cN2(4个可疑腋窝淋巴结/内乳淋巴结转移)。根据[F]FDG全身PET-MR和乳腺MR检查结果,[F]FDG全身PET-MR(包括整合的乳腺MR方案)使2例患者的临床肿瘤状态和9例患者的临床淋巴结状态分期上调。此外,3例患者检测到远处转移(肝脏/骨),另1例患者被诊断为同步原发性肿瘤(肺癌)。
[F]FDG全身PET-MR,包括在乳腺癌患者单一方案中进行乳腺MR整合,是可行的,并且在乳腺癌患者的局部区域和远处分期方面提供了一种有前景的新方法。关键相关性声明:[F]FDG全身PET-MR,包括整合的乳腺MR方案,是可行的,并且能够在乳腺癌患者的单次成像检查中实现局部区域和远处分期。
[F]FDG PET-MR允许乳腺MR和全身分期联合进行。因此,研究了包括整合乳腺MRI的全身[F]FDG PET-MR单一方案。[F]FDG PET-MR,包括整合的乳腺MR是可行的,并且可以在日常临床实践中考虑应用。